TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the serum insulin concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Canine retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Orthodontic outcomes
Primary endpoint: Molar mesial drift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Orthodontic outcomes
Primary endpoint: Number of Participants With at Least 1 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of hrHPV positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical Global Impressions - Improvement Scale (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response of muscle mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of survival
Endpoint domain: Mortality/survival
Primary endpoint: mortality within 28 days after ICU admission
Endpoint domain: Mortality/survival
Primary endpoint: Urine Protein to Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of nebulizations required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of brain waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quantification of selected emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of independence for walking 150 feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking speed for 50 feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perioperative Opioid Use
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the 6-minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Mean Pulmonary Arterial Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Pulmonary Vascular Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Cardiac Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of serum potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decision-Regret
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Grade 3+ Gastrointestinal Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Compliance with nutritional supplement recommendation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amount of food consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hematological and non-hematological toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting Toxicity (DLT) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Endoscopic Remission of Ulcerative Colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage change in serum LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lacrimal drainage resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in COWA Unique Word Count
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Spontaneous Narrative Raw Word Count
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change of BMI-SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GMTs for IgG Against OspA Serotypes ST1 to ST6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of the crusting stage of VZV rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline Clinical Global Impression Scale (CGI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of My 5 Moments for Hand Hygiene
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of performing My 5 Moments for Hand Hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitude on hand hygiene
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of delayed CINV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of blood losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oculo-Cognitive Addition Test (OCAT) Completion Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Saccadic Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fixation Time - Low Cognitive Workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentration of Fluconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of acquired consonants produced by the child
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiac death, target vessel myocardial infarction (MI) and clinically driven target lesion revascularization (TLR)
Endpoint domain: Mortality/survival
Primary endpoint: Ileal sphingomyelin output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: DHA+PQP AUC and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A/DHA/L AUC and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TQ AUC and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall risk evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Inflammation conditions in the anterior ocular chamber
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Nicotine Craving Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant changes from baseline in safety assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters: Cmax, Tmax, AUC 0-24 h, T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostaglandin E2 (PGE2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prostaglandin F2a (PGF2a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thromboxane B2 (TxB2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 15-Hydroxyeicosatetraenoic Acid (15-HETE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major Pathologic Response Rate (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of VST at 30 days as measured by viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of early serum trough concentrations of risankizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive value of early anti-drug antibodies of risankizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of the therapeutic window of risankizumab in psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pulmonary Artery Pressure (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pulmonary Artery Oxygen Saturation (PAO2%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anterior cruciate ligament injury comprehension percent correct
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Zarit Caregiver Burden scores over time
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: use of breast-feeding
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of patients who achieve SVR12 who started on direct-acting antiviral therapy for chronic hepatitis C infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of filter patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemolysis marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse event occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Cases of CDI
Endpoint domain: Adverse events/effects
Primary endpoint: Relative Tumor Size Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the serum concentration time curve (AUC) of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration (Cmax) of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Synkinesis Assessment Questionnaire (SAQ) Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Personal anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Actual anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fugl-Meyer Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional independence measure (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Box and Block test (BBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antioxidant activity (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL/HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidences of adverse events or serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of bone substitute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of osseointegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance between weight and tessitura threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Logical Memory I (Immediate)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: arterial pO2 on room air
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: graded changes in blood oxygen level-dependent (BOLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: variations in GABA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean daily Combined Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Thrombolysis in Cerebral Infarction (mTICI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Occurrence of serious Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Lab Abnormalities Grade 3-4
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy rate at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Abstinence from substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term safety of the Parachute system
Endpoint domain: Adverse events/effects
Primary endpoint: Change from pre- to posttreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA response decline > 50% after therapy with docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA response decline > 50% after therapy with enzalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with complications or open conversion to M-LC
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum hemoglobin achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency of the Zenith® Spiral-Z® AAA Iliac Leg Graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nifedipine blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Auditory Hallucination Rating Scale (AHRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fecal Excretion of LY3023703 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary Excretion of LY3023703 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of patients having successful disimpaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time when patients having successful disimpaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IDS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response (RECIST 1.1 Partial plus complete)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 15D - instrument
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Success rate of admittance to initial planned oncological treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline Measured as Global Response Assessment (GRA) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in liver saturated lipid index (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Cerebrospinal Fluid (CSF) Leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Supplemental Opioid Use
Endpoint domain: Adverse events/effects
Primary endpoint: Conjunctival Staining at 1 Minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Thrombotic Microangiopathy (TMA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of ROC for diagnosis of appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with reduced Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Abnormal Blinded Visual PET Image Interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity Percentage of Blinded Visual PET Image Interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of lymphatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Saccades execution parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: visceral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver function biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fast Ultrasound Attenuation Parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Daily Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in α-diversity in saliva samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Pathologic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of Interleukin 6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Value of Angiopoietin 2 (Ang-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of Syndecan-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of Heparan sulfate (HS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolomics profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food choices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal choices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily intakes of dairy products, vegetables and fruits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adequate Relief of Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of periodontal health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Periodontal health status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standing cough stress test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from SoundBite™ Crossing System related MAEs at 30 days post procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with CR or PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite Sleep Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Enlarged mediastinal lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Changes in Health-related quality of life score compared to baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Tumor response compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Variation in Serum Levels of Procollagen 1 N-terminal Peptide (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in Serum Carboxy-terminal Telopeptide of Collagen Type I (sCTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in Circulating Osteoprogenitor Cells (OPCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammatory markers including C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect on Mesenchymal stem cell function including cell migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of compensated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in Fall Risk Assessment Tool (FRAT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in fall rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Abnormalities in Safety Assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Completely Healed Wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Size Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Spontaneous Reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in symptoms of posttraumatic stress disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 Hour C-peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of CTX mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With ICU Mortality
Endpoint domain: Mortality/survival
Primary endpoint: All Cause Mortality at 28 Days
Endpoint domain: Mortality/survival
Primary endpoint: Sudoscan values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline Adjusted AUC of Minimal Cross-Sectional Area of Nasal Cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes